Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

30.46
-1.6300-5.08%
Post-market: 30.460.00000.00%16:34 EDT
Volume:693.96K
Turnover:21.38M
Market Cap:2.67B
PE:-23.71
High:32.05
Open:31.90
Low:30.36
Close:32.09
52wk High:39.28
52wk Low:13.45
Shares:87.67M
Float Shares:81.82M
Volume Ratio:0.49
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2849
EPS(LYR):-1.2849
ROE:-10.92%
ROA:-8.92%
PB:2.61
PE(LYR):-23.71

Loading ...

BRIEF-Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Feb 27

IDEAYA Biosciences Grants 346,200 Inducement Stock Options to New Hires

Reuters
·
Feb 27

BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc

Reuters
·
Feb 25

IDEAYA Biosciences Enrolls First Patient in Phase 1 IDE034 Trial

Reuters
·
Feb 25

IDEAYA Biosciences Inc - First Patient Dosing With Ide034 Triggers $5 Mln Payment to Biocytogen

THOMSON REUTERS
·
Feb 25

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Trial of Ide034, a Potential First-in-Class B7h3/Ptk7 Bispecific Top1 ADC

THOMSON REUTERS
·
Feb 25

IDEAYA Biosciences Names Dr. Theodora Ross Chief Development Officer

Reuters
·
Feb 23

IDEAYA Biosciences Announces Appointment of DR. Theodora (Theo) Ross, M.d., Ph.d., as Chief Development Officer

THOMSON REUTERS
·
Feb 23

IDEAYA Biosciences: Pipeline Progress and Late-Stage Clinical Expansion Support Reiterated Buy Rating

TIPRANKS
·
Feb 21

IDEAYA Biosciences Is Maintained at Buy by Citigroup

Dow Jones
·
Feb 20

Stock Track | IDEAYA Biosciences Soars 5.11% Intraday on Wells Fargo's Bullish Analyst Rating

Stock Track
·
Feb 20

Wells Fargo Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
Feb 19

IDEAYA Biosciences Is Maintained at Outperform by Wedbush

Dow Jones
·
Feb 18

Ideaya Biosciences price target raised to $52 from $49 at Wedbush

TIPRANKS
·
Feb 18

RBC Capital Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
Feb 18

IDEAYA Biosciences: Buy Rating on Darovasertib/Crizotinib Ahead of Pivotal OpतimUM-02 Readout and Supported by Strong Cash Runway

TIPRANKS
·
Feb 18

Wedbush Adjusts IDEAYA Biosciences Price Target to $52 From $49, Maintains Outperform Rating

MT Newswires Live
·
Feb 18

Ideaya Biosciences Q4 Net Loss Narrows as Revenue Rises

MT Newswires Live
·
Feb 17

IDEAYA Q4 profit slightly beats estimates

Reuters
·
Feb 17

IDEAYA Biosciences Q4 2025 EPS $(0.94), Inline, Sales $10.876M Beat $6.241M Estimate

Benzinga
·
Feb 17